IMPACTfolio LLC Invests $215,000 in Edwards Lifesciences Co. (NYSE:EW)

IMPACTfolio LLC acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 2,904 shares of the medical research company’s stock, valued at approximately $215,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter valued at approximately $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at $32,000. Avior Wealth Management LLC raised its holdings in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares during the period. Peoples Bank KS acquired a new position in Edwards Lifesciences during the 3rd quarter worth $40,000. Finally, JFS Wealth Advisors LLC boosted its holdings in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 166 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 1.8 %

Shares of NYSE:EW traded down $1.34 during trading on Thursday, hitting $72.69. 3,399,019 shares of the company’s stock were exchanged, compared to its average volume of 4,694,415. The firm has a 50-day moving average price of $70.94 and a two-hundred day moving average price of $72.83. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm has a market cap of $42.87 billion, a P/E ratio of 10.49, a PEG ratio of 3.63 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the firm earned $0.59 earnings per share. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. Equities analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,500 shares of company stock worth $2,508,350 in the last quarter. Corporate insiders own 1.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on EW shares. UBS Group reduced their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. The Goldman Sachs Group boosted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, Wells Fargo & Company reduced their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Sixteen analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $79.40.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.